Dr. Joel M. Neutel

Internal Medicine
14351 Myford Rd, Suite B, 
Tustin, CA 
Clinical Trials:Currently Recruiting for 1 Trial
14351 Myford Rd, Suite B, 
Tustin, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joel Neutel is a primary care provider, practicing in Internal Medicine in Tustin, California. Dr. Neutel is rated as an Experienced provider by MediFind in the treatment of Pompe Disease. His top areas of expertise are Hypertension, Type 2 Diabetes (T2D), Low Blood Sugar, and Obesity.

His clinical research consists of co-authoring 81 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

14351 Myford Rd, Suite B, Tustin, CA 92780

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype
A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype
Enrollment Status: Recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Single Dose, Open Label Pharmacokinetic Study of Omaveloxolone in Subjects With Mild, Moderate, or Severe Hepatic Impairment, or With Normal Hepatic Function
A Single Dose, Open Label Pharmacokinetic Study of Omaveloxolone in Subjects With Mild, Moderate, or Severe Hepatic Impairment, or With Normal Hepatic Function
Enrollment Status: Completed
Publish Date: May 30, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Drug: Orticumab
Study Phase: Phase 2
A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment
A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment
Enrollment Status: Completed
Publish Date: March 24, 2023
Intervention Type: Drug
Study Phase: Phase 1
Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function
Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function
Enrollment Status: Completed
Publish Date: March 23, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study To Assess The Effect Of Moderate Renal Impairment On The Pharmacokinetics Of Surufatinib
A Phase 1 Study To Assess The Effect Of Moderate Renal Impairment On The Pharmacokinetics Of Surufatinib
Enrollment Status: Completed
Publish Date: November 03, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study To Assess The Effect Of Hepatic Impairment On The Pharmacokinetics Of Surufatinib
A Phase 1 Study To Assess The Effect Of Hepatic Impairment On The Pharmacokinetics Of Surufatinib
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea
A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea
Enrollment Status: Completed
Publish Date: October 22, 2021
Intervention Type: Drug
Study Drug: Crofelemer delayed-release tablets
Study Phase: Phase 4
A Randomized, Double-blind, Parallel, Vehicle Controlled, Repeat Dose Comparative Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD-1 in Rheumatoid Arthritis Patients With Mild Disease Managed With DMARDs
A Randomized, Double-blind, Parallel, Vehicle Controlled, Repeat Dose Comparative Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD-1 in Rheumatoid Arthritis Patients With Mild Disease Managed With DMARDs
Enrollment Status: Completed
Publish Date: October 19, 2021
Intervention Type: Drug
Study Drug: ORTD-1
Study Phase: Phase 1
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label, Non-randomized, Single-dose, Parallel-group, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib Administered at 300 mg in Fasted, Hepatically-impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects
An Open-label, Non-randomized, Single-dose, Parallel-group, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib Administered at 300 mg in Fasted, Hepatically-impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects
Enrollment Status: Completed
Publish Date: May 20, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
Enrollment Status: Completed
Publish Date: February 15, 2019
Intervention Type: Drug
Study Phase: Phase 2
Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment
Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment
Enrollment Status: Withdrawn
Publish Date: June 28, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 13 Less Clinical Trials

81 Total Publications

Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.
Journal: JAMA
Published: May 28, 2025
Similar Doctors
Advanced in Pompe Disease
Dr. Magdi S. Elsaadi
Internal Medicine
Advanced in Pompe Disease
Dr. Magdi S. Elsaadi
Internal Medicine
1738 N Waterman Ave, Suite 7, 
San Bernardino, CA 
 (41.5 miles away)
909-881-9918
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Magdi Elsaadi is a primary care provider, practicing in Internal Medicine in San Bernardino, California. Dr. Elsaadi is rated as an Advanced provider by MediFind in the treatment of Pompe Disease. His top areas of expertise are Pompe Disease, Danon Disease, Type 2 Diabetes (T2D), and High Cholesterol.

Experienced in Pompe Disease
Dr. B'lala Nawurah
Internal Medicine
Experienced in Pompe Disease
Dr. B'lala Nawurah
Internal Medicine

Beaver Medical Group P C

5957 W Ramsey St, 
Banning, CA 
 (51.6 miles away)
951-845-0313
Languages Spoken:
English
See accepted insurances
Accepting New Patients

B'lala Nawurah is a primary care provider, practicing in Internal Medicine in Banning, California. Dr. Nawurah is rated as an Advanced provider by MediFind in the treatment of Pompe Disease. Her top areas of expertise are Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, Familial Combined Hyperlipidemia, and Xanthoma. Dr. Nawurah is currently accepting new patients.

Experienced in Pompe Disease
Dr. Marvin L. Elias
Internal Medicine
Experienced in Pompe Disease
Dr. Marvin L. Elias
Internal Medicine

Faculty Physicians And Surgeons Of Llusm

25828 Redlands Blvd, Suite 102, 
Redlands, CA 
 (40.2 miles away)
909-558-6600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marvin Elias is a primary care provider, practicing in Internal Medicine in Redlands, California. Dr. Elias is rated as a Distinguished provider by MediFind in the treatment of Pompe Disease. His top areas of expertise are Type 2 Diabetes (T2D), Osteomyelitis in Children, Diabetic Nephropathy, and Anal Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Neutel's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile